hLL1
A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. hLL1 is a type of monoclonal antibody. Also called IMMU-110 and milatuzumab.
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
antibody (AN-tee-BAH-dee)
A protein made by plasma cells (a type of white blood cell) in response to an antigen (a substance that causes the body to make a specific immune response). Each antibody can bind to only one specific antigen. The purpose of this binding is to help destroy the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
cancer (KAN-ser)
A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of cancer. Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are cancers that begin in the cells of the immune system. Central nervous system cancers are cancers that begin in the tissues of the brain and spinal cord. Also called malignancy.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
hLL1
A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. hLL1 is a type of monoclonal antibody. Also called IMMU-110 and milatuzumab.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
IMMU-110
A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. IMMU-110 is a type of monoclonal antibody. Also called hLL1 and milatuzumab.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
milatuzumab (MIH-luh-TOO-zoo-mab)
A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. Milatuzumab is a type of monoclonal antibody. Also called hLL1 and IMMU-110.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
multiple myeloma (MUL-tih-pul MY-eh-LOH-muh)
A type of cancer that begins in plasma cells (white blood cells that produce antibodies). Also called Kahler disease, myelomatosis, and plasma cell myeloma.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
myeloma (MY-eh-LOH-muh)
Cancer that arises in plasma cells, a type of white blood cell.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
protein (PROH-teen)
A molecule made up of amino acids that are needed for the body to function properly. Proteins are the basis of body structures such as skin and hair and of substances such as enzymes, cytokines, and antibodies.
Source: The National Cancer Institute's Dictionary of Cancer Terms(http://www.cancer.gov/dictionary)
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
(http://www.cancer.gov/dictionary)
Inside MSKCC
|
©2013 Memorial Sloan-Kettering Cancer Center